中國醫藥大學機構典藏 China Medical University Repository, Taiwan:Item 310903500/43869
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 29490/55136 (53%)
造訪人次 : 1506441      線上人數 : 685
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於CMUR ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/43869


    題名: A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
    作者: (Wen-Wei Sung);Yao-Chen Wan;(Ya-Wen Cheng);(Ming-Ching Lee);(Kun-Tu Yeh);(Lee Wang);(John Wang);陳志毅(Chih-Yi Chen);(Huei Lee)*
    貢獻者: 健康照護學院二年制呼吸治療學系;中國附醫癌症中心
    關鍵詞: FasL -844T/C;NSCLC
    日期: 2011-09
    上傳時間: 2012-04-19 11:25:18 (UTC+8)
    摘要: Purpose:Fas ligand (FasL) −844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL −844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL −844T/C polymorphism on the clinical outcome of non–small cell lung cancer (NSCLC) remains to be identified.

    Experimental Design: A total of 385 adjacent normal lung tissues from patients with NSCLC were collected to determine FasL −844T/C polymorphism by PCR-based restriction fragment length polymorphism. FasL mRNA and protein expression in lung tumors were evaluated by real-time PCR and immunohistochemistry. The prognostic value of FasL −844T/C polymorphism on survival and relapse was determined by Kaplan–Meier analysis and Cox proportional hazards models.

    Results: The FasL −844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors (P = 0.008). In addition, patients with the FasL −844CC genotype were more prone to tumor relapse than those with the FasL −844TT+TC genotype (62.1% vs. 37.9%, P = 0.001). Multivariate Cox regression analysis showed that patients with the FasL −844CC genotype had poorer survival in terms of overall survival (OS) and relapse-free survival (RFS) than those with the FasL −844TT+TC genotype (24.1 vs. 42.8 months for OS, HR = 1.455, P = 0.004; 15.4 vs. 31.4 months for RFS, HR = 1.710, P < 0.001).

    Conclusions:FasL −844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group.
    關聯: CLINICAL CANCER RESEARCH 17(18):5991-5999
    顯示於類別:[二年制呼吸治療學系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML237檢視/開啟


    在CMUR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

     

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋